CYTK
Price
$50.78Alerts
Change
-$0.68 (-1.32%)
Updated
Nov 20 closing price
Capitalization
7.46B
101 days until earnings call
Intraday BUY SELL Signals
NAMS
Price
$18.41Alerts
Change
-$1.10 (-5.64%)
Updated
Nov 20 closing price
Capitalization
2.26B
102 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CYTK vs NAMS

CYTK vs NAMS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CYTK vs. NAMS commentary
Nov 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a Hold and NAMS is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CYTK with price predictions
Nov 20, 2026

CYTK's Indicator enters downward trend

The Aroon Indicator for CYTK entered a downward trend on November 19, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 173 similar instances where the Aroon Indicator formed such a pattern. In 152 of the 173 cases the stock moved lower. This puts the odds of a downward move at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CYTK as a result. In 78 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for CYTK turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In 44 of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.

The 50-day moving average for CYTK moved below the 200-day moving average on October 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYTK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +6.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where CYTK advanced for three days, in 212 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.

CYTK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. CYTK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 83 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYTK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-43.024) is normal, around the industry mean (3.596). P/E Ratio (-7.436) is within average values for comparable stocks, (-1.186). CYTK's Projected Growth (PEG Ratio) (82.230) is slightly higher than the industry average of (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (128.205) is also within normal values, averaging (443.347).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for NAMS with price predictions
Nov 20, 2026

NAMS's Indicator enters downward trend

The Aroon Indicator for NAMS entered a downward trend on November 18, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 174 similar instances where the Aroon Indicator formed such a pattern. In 149 of the 174 cases the stock moved lower. This puts the odds of a downward move at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NAMS as a result. In 57 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 61%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NAMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NAMS's RSI Oscillator exited the oversold zone, 19 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 61 cases where NAMS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.

The Moving Average Convergence Divergence (MACD) for NAMS just turned positive on November 11, 2026. Looking at past instances where NAMS's MACD turned positive, the stock continued to rise in 41 of 57 cases over the following month. The odds of a continued upward trend are 72%.

Following a +9.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where NAMS advanced for three days, in 202 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.578) is normal, around the industry mean (3.596). P/E Ratio (-8.750) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (357.143) is also within normal values, averaging (443.347).

The Tickeron Profit vs. Risk Rating rating for this company is 70 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NAMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. NAMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
CYTK: Fundamental Ratings
CYTK
OUTLOOK RATING
1..100
82
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
PROFIT vs RISK RATING
1..100
83
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
78
P/E GROWTH RATING
1..100
15
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CYTKNAMS
RSI
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 4 days ago
68%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
61%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
72%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 11 days ago
72%
Bullish Trend 11 days ago
80%
Declines
ODDS (%)
Bearish Trend 4 days ago
79%
Bearish Trend 2 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
68%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
86%
COMPARISON
Comparison
Nov 22, 2026
Stock price -- (CYTK: $50.78 vs. NAMS: $18.41)
Brand notoriety: CYTK and NAMS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 64% vs. NAMS: 89%
Market capitalization -- CYTK: $7.46B vs. NAMS: $2.26B
CYTK [@Biotechnology] is valued at $7.46B. NAMS’s [@Biotechnology] market capitalization is $2.26B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green while NAMS’s FA Score has 2 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • NAMS’s FA Score: 2 green, 3 red.
According to our system of comparison, NAMS is a better buy in the long-term than CYTK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 4 TA indicator(s) are bullish while NAMS’s TA Score has 4 bullish TA indicator(s).

  • CYTK’s TA Score: 4 bullish, 5 bearish.
  • NAMS’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, NAMS is a better buy in the short-term than CYTK.

Price Growth

CYTK (@Biotechnology) experienced а -9.53% price change this week, while NAMS (@Biotechnology) price change was -8.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.58%. For the same industry, the average monthly price growth was -18.26%, and the average quarterly price growth was -28.15%.

Reported Earning Dates

CYTK is expected to report earnings on Mar 02, 2027.

NAMS is expected to report earnings on Mar 03, 2027.

Industries' Descriptions

@Biotechnology (-11.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

NAMS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with SLDB. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then SLDB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
-5.64%
SLDB - NAMS
47%
Loosely correlated
-2.95%
IMVT - NAMS
46%
Loosely correlated
-2.31%
PTCT - NAMS
45%
Loosely correlated
-3.27%
VKTX - NAMS
45%
Loosely correlated
-4.14%
FDMT - NAMS
44%
Loosely correlated
-4.57%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
JMUB48.800.18
+0.37%
JPMorgan Municipal ETF (JMUB)
BSGR25.060.01
+0.06%
Invesco BulletShares 2027 Treasury Bond ETF (BSGR)
FLUD24.94-0.01
-0.04%
Franklin Ultra Short Bond ETF (FLUD)
KOCT36.04-0.66
-1.79%
Innovator U.S. Small Cap Power Buffer ETF - October (KOCT)
GXRP17.13-1.49
-8.00%
Grayscale XRP Trust ETF (GXRP)